Clinical Trials
9 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05308446 2026-04-21
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT04963283 2026-03-31
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT03026140 2026-03-05
NICHE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03350126 2025-07-23
NIPICOL
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT03442569 2025-07-01
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03642067 2025-06-15
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03631641 2024-07-01
Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated